Top

Published in:

03-07-2024 | Other Specific Types of Diabetes | Review

Immune checkpoint inhibitors-induced diabetes mellitus (review)

Authors: Jiayi Chen, Xiaochen Hou, Yang Yang, Chenxi Wang, Jie Zhou, Jingge Miao, Fuhong Gong, Fei Ge, Wenlin Chen

Published in: Endocrine | Issue 2/2024

Abstract

Immune checkpoint inhibitors (ICIs) have become extensively utilized in the early-stage treatment of various cancers, offering additional therapeutic possibilities for patients with advanced cancer. However, certain patient populations are susceptible to experiencing toxic adverse effects from ICIs, such as thyrotoxicosis, rashes, among others. Specifically, ICIDM, induced by immune checkpoint inhibitors, exhibits characteristics similar to insulin-dependent diabetes mellitus (Type 1 Diabetes Mellitus, T1DM). ICIDM is characterized by a rapid onset and may coincide with severe ketoacidosis. Despite a favorable response to insulin therapy, patients typically require lifelong insulin dependence. After discussing the autoimmune adverse effects and the specifics of ICIs-induced diabetes mellitus (ICIDM), it is important to note that certain patient populations are particularly susceptible to experiencing toxic adverse effects from ICIs. Specifically, ICIDM, which is triggered by immune checkpoint inhibitors, mirrors the characteristics of insulin-dependent diabetes mellitus (Type 1 Diabetes Mellitus, T1DM). This article conducts an in-depth analysis of the literature to explore the pathogenesis, disease progression, and treatment strategies applicable to diabetes induced by immune checkpoint inhibitors (ICIDM).

A.L. Perdigoto, Z. Quandt, M. Anderson, K.C. Herold, Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome. Lancet Diabetes Endocrinol. 7(6), 421–423 (2019). https://doi.org/10.1016/S2213-8587(19)30072-5.CrossRefPubMed

K. Shimada, H. Yamamoto, E. Nakatani et al. Real-world evidence of the incidence of and risk factors for type 1 diabetes mellitus and hypothyroidism as immune-related adverse events associated with programmed cell death-1 inhibitors. Endocr. Pract. 27(6), 586–593 (2021). https://doi.org/10.1016/j.eprac.2020.12.009.CrossRefPubMed

A.M. Stamatouli, Z. Quandt, A.L. Perdigoto et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes 67(8), 1471–1480 (2018). https://doi.org/10.2337/dbi18-0002.CrossRefPubMedPubMedCentral

S. Qin, L. Xu, M. Yi, S. Yu, K. Wu, S. Luo, Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol. Cancer. 18(1), 155 (2019). https://doi.org/10.1186/s12943-019-1091-2.CrossRefPubMedPubMedCentral

E. Raschi, M. Gatti, F. Gelsomino, A. Ardizzoni, E. Poluzzi, F. De Ponti, Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance. Target Oncol. 15(4), 449–466 (2020). https://doi.org/10.1007/s11523-020-00738-6.CrossRefPubMedPubMedCentral

A. Zand Irani, A. Almuwais, H. Gibbons, Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab. BMJ Case Rep. 15(1), e245846 (2022). https://doi.org/10.1136/bcr-2021-245846.CrossRefPubMedPubMedCentral

A. Zand Irani, H. Gibbons, I. WX, Immune checkpoint inhibitor-induced diabetes mellitus with nivolumab. BMJ Case Rep. 16(4), e253696 (2023). https://doi.org/10.1136/bcr-2022-253696.CrossRefPubMedPubMedCentral

M. Shiba, H. Inaba, H. Ariyasu et al. Fulminant type 1 diabetes mellitus accompanied by positive conversion of anti-insulin antibody after the administration of anti-CTLA-4 antibody following the discontinuation of Anti-PD-1 antibody. Intern. Med. 57(14), 2029–2034 (2018). https://doi.org/10.2169/internalmedicine.9518-17.CrossRefPubMedPubMedCentral

M. Zezza, C. Kosinski, C. Mekoguem et al. Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports. BMC Endocr. Disord. 19(1), 144 (2019). https://doi.org/10.1186/s12902-019-0467-z.CrossRefPubMedPubMedCentral

10.

P.Y. Chan, P. Hall, G. Hay, V.M.L. Cohen, P.W. Szlosarek, A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity. Pigment. Cell Melanoma Res. 30(6), 558–562 (2017). https://doi.org/10.1111/pcmr.12607.CrossRefPubMed

11.

V.H.M. Tsang, R.T. McGrath, R.J. Clifton-Bligh et al. Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes. J. Clin. Endocrinol. Metab. 104(11), 5499–5506 (2019). https://doi.org/10.1210/jc.2019-00423.CrossRefPubMed

12.

A. Kotwal, C. Haddox, M. Block, Y.C. Kudva, Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res. Care. 7(1), e000591 (2019). https://doi.org/10.1136/bmjdrc-2018-000591.CrossRefPubMedPubMedCentral

13.

X. Chen, A.H. Affinati, Y. Lee, A.F. Turcu, N.L. Henry, E. Schiopu, A. Qin, M. Othus, D. Clauw, N. Ramnath, L. Zhao, Immune checkpoint inhibitors and risk of type 1 diabetes. Diabetes Care. 45(5), 1170–1176 (2022). https://doi.org/10.2337/dc21-2213.CrossRefPubMedPubMedCentral

14.

D.J. Byun, R. Braunstein, J. Flynn, J. Zheng, R.A. Lefkowitz, S. Kanbour, M. Girotra, Immune checkpoint inhibitor-associated diabetes: a single-institution experience. Diabetes Care. 43(12), 3106–3109 (2020). https://doi.org/10.2337/dc20-0609.CrossRefPubMedPubMedCentral

15.

J.A. Pearson, F.S. Wong, L. Wen, The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes. J. Autoimmun. 66, 76–88 (2016). https://doi.org/10.1016/j.jaut.2015.08.019.CrossRefPubMed

16.

M.E. Keir, S.C. Liang, I. Guleria, Y.E. Latchman, A. Qipo, L.A. Albacker, M. Koulmanda, G.J. Freeman, M.H. Sayegh, A.H. Sharpe, Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203(4), 883–895 (2006). https://doi.org/10.1084/jem.20051776.CrossRefPubMedPubMedCentral

17.

N. Youssef, M. Noureldein, G. Daoud, A.A. Eid, Immune checkpoint inhibitors and diabetes: Mechanisms and predictors. Diabetes Metab. 47(3), 101193 (2021). https://doi.org/10.1016/j.diabet.2020.09.003.CrossRefPubMed

18.

M.J. Ansari, A.D. Salama, T. Chitnis, R.N. Smith, H. Yagita, H. Akiba, T. Yamazaki, M. Azuma, H. Iwai, S.J. Khoury, H. Auchincloss Jr, M.H. Sayegh, The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 198(1), 63–69 (2003). https://doi.org/10.1084/jem.20022125.CrossRefPubMedPubMedCentral

19.

T.J. Won, Y.J. Jung, S.J. Kwon, Y.J. Lee, D.I. Lee, H. Min, E.S. Park, S.S. Joo, K.W. Hwang, Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetes. Arch. Pharm. Res. 33(11), 1825–1833 (2010). https://doi.org/10.1007/s12272-010-1115-3.CrossRefPubMed

20.

J. Cantor, K. Haskins, Recruitment and activation of macrophages by pathogenic CD4 T cells in type 1 diabetes: evidence for involvement of CCR8 and CCL1. J. Immunol. 179(9), 5760–5767 (2007). https://doi.org/10.4049/jimmunol.179.9.5760.CrossRefPubMed

21.

N. Alonso, B. Soldevila, A. Sanmartí, R. Pujol-Borrell, E. Martínez-Cáceres, Regulatory T cells in diabetes and gastritis. Autoimmun. Rev. 8(8), 659–662 (2009). https://doi.org/10.1016/j.autrev.2009.02.014.CrossRefPubMed

22.

D. Mourad, N.S. Azar, A.A. Eid, S.T. Azar, Immune checkpoint inhibitor-induced diabetes mellitus: potential role of t cells in the underlying mechanism. Int. J. Mol. Sci. 22(4), 2093 (2021). https://doi.org/10.3390/ijms22042093.CrossRefPubMedPubMedCentral

23.

J.A. Noble, Immunogenetics of type 1 diabetes: a comprehensive review. J. Autoimmun. 64, 101–112 (2015). https://doi.org/10.1016/j.jaut.2015.07.014.CrossRefPubMed

24.

H. Erlich, A.M. Valdes, J. Noble, J.A. Carlson, M. Varney, P. Concannon et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 57(4), 1084–1092 (2008). https://doi.org/10.2337/db07-1331.CrossRefPubMed

25.

Y.C. Liu, H. Liu, S.L. Zhao, K. Chen, P. Jin, Clinical and HLA genotype analysis of immune checkpoint inhibitor-associated diabetes mellitus: a single-center case series from China. Front. Immunol. 14, 1164120 (2023). https://doi.org/10.3389/fimmu.2023.1164120.CrossRefPubMedPubMedCentral

26.

V. Lo Preiato, S. Salvagni, C. Ricci, A. Ardizzoni, U. Pagotto, C. Pelusi, Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature. Rev. Endocr. Metab. Disord. 22(2), 337–349 (2021). https://doi.org/10.1007/s11154-020-09618-w.CrossRefPubMed

27.

J. Kapke, Z. Shaheen, D. Kilari, P. Knudson, S. Wong, Immune checkpoint inhibitor-associated type 1 diabetes mellitus: case series, review of the Literature, and optimal management. Case Rep. Oncol. 10(3), 897–909 (2017).CrossRefPubMedPubMedCentral

28.

Y. Miyoshi, O. Ogawa, Y. Oyama, Nivolumab, an anti-programmed cell Death-1 antibody, induces fulminant type 1 diabetes. Tohoku J. Exp. Med. 239(2), 155–158 (2016).CrossRefPubMed

29.

A. Fukui, K. Sugiyama, T. Yamada, A case of nivolumab-induced fulminant type 1 diabetes with steroids and glucagon-like peptide 1 administration during the early onset. J. Clin. Case Rep. 6, 11 (2016).CrossRef

30.

J.R. Lowe, D.J. Perry, A.K. Salama, C.E. Mathews, L.G. Moss, B.A. Hanks, Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. J. Immunother Cancer. 4, 89 (2016). https://doi.org/10.1186/s40425-016-0196-z.CrossRefPubMedPubMedCentral

31.

V.H.M. L, Tsang, S.C. Sasson, A.M. Menzies, M.S. Carlino, D.A. Brown, R. Clifton-Bligh, J.E. Gunton, Unravelling checkpoint inhibitor associated autoimmune diabetes: from bench to bedside. Front. Endocrinol. 12, 764138 (2021). https://doi.org/10.3389/fendo.2021.764138.CrossRef

32.

J. Suh, H.I. Lee, M. Lee, K. Song, H.S. Choi, A. Kwon, H.S. Kim, H.W. Chae, Insulin requirement and complications associated with serum C-peptide decline in patients with type 1 diabetes mellitus during 15 years after diagnosis. Front. Endocrinol. 13, 869204 (2022). https://doi.org/10.3389/fendo.2022.869204.CrossRef

33.

J.H. Seo, T. Lim, A. Ham, Y.A. Kim, M. Lee, New-onset type 1 diabetes mellitus as a delayed immune-related event after discontinuation of nivolumab: a case report. Medicine 101(35), e30456 (2022). https://doi.org/10.1097/MD.0000000000030456.CrossRefPubMedPubMedCentral

34.

Phang C.A., Kumar S., Rohl P. Acute presentation of immunotherapy-related diabetes mellitus without ketoacidosis, low C-peptide or elevated HbA1c. Endocrinol Diabetes Metab Case Rep. Published online November 1, 2022. https://doi.org/10.1530/EDM-22-0291.

35.

J. Sothornwit, A. Phunmanee, C. Pongchaiyakul, Atezolizumab-induced autoimmune diabetes in a patient with metastatic lung cancer. Front Endocrinol. 10, 352 (2019). https://doi.org/10.3389/fendo.2019.00352.CrossRef

36.

H.A. Keenan, J.K. Sun, J. Levine, A. Doria, L.P. Aiello, G. Eisenbarth, S. Bonner-Weir, G.L. King, Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes. 59(11), 2846–2853 (2010). https://doi.org/10.2337/db10-0676.CrossRefPubMedPubMedCentral

37.

F. Thorel, V. Népote, I. Avril, K. Kohno, R. Desgraz, S. Chera, P.L. Herrera, Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature. 464(7292), 1149–1154 (2010). https://doi.org/10.1038/nature08894.CrossRefPubMedPubMedCentral

38.

A.M. Dimarino, A.I. Caplan, T.L. Bonfield, Mesenchymal stem cells in tissue repair. Front Immunol. 4, 201 (2013). https://doi.org/10.3389/fimmu.2013.00201.CrossRefPubMedPubMedCentral

39.

R. Abdi, P. Fiorina, C.N. Adra, M. Atkinson, M.H. Sayegh, Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes. 57(7), 1759–1767 (2008). https://doi.org/10.2337/db08-0180.CrossRefPubMedPubMedCentral

40.

E. Kawada-Horitani, S. Kita, T. Okita, Y. Nakamura, H. Nishida, Y. Honma, S. Fukuda, Y. Tsugawa-Shimizu, J. Kozawa, T. Sakaue, Y. Kawachi, Y. Fujishima, H. Nishizawa, M. Azuma, N. Maeda, I. Shimomura, Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade. Diabetologia. 65(7), 1185–1197 (2022). https://doi.org/10.1007/s00125-022-05708-3.CrossRefPubMedPubMedCentral

41.

P.O. Carlsson, D. Espes, S. Sisay, L.C. Davies, C.I.E. Smith, M.G. Svahn, Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a Phase I/II andomized double-blind placebo-controlled trial. Diabetologia. 66(8), 1431–1441 (2023). https://doi.org/10.1007/s00125-023-05934-3.CrossRefPubMedPubMedCentral

42.

P.O. Carlsson, D. Espes, S. Sisay, L.C. Davies, C.I.E. Smith, M.G. Svahn, Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a Phase I/II randomised double-blind placebo-controlled trial. Diabetologia. 66(8), 1431–1441 (2023). https://doi.org/10.1007/s00125-023-05934-3.CrossRefPubMedPubMedCentral

Title: Immune checkpoint inhibitors-induced diabetes mellitus (review)
Authors: Jiayi Chen
Xiaochen Hou
Yang Yang
Chenxi Wang
Jie Zhou
Jingge Miao
Fuhong Gong
Fei Ge
Wenlin Chen
Publication date: 03-07-2024
Publisher: Springer US
Keywords: Other Specific Types of Diabetes
Medical Side Effect
Checkpoint Inhibitors
Type 1 Diabetes
Diabetes
Insulins
Endocrinology
Insulins
Published in: Endocrine / Issue 2/2024
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-024-03942-w

Correction: Novel protective circulating miRNA are associated with preserved vitamin D levels in patients with mild COVID-19 presentation at hospital admission not progressing into severe disease

Open Access
Correction

BMI z-score as a prognostic factor for height velocity in children treated with recombinant human growth hormone due to idiopathic growth hormone deficiency

Open Access
Original Article

Plasma oxytocin levels in response to glucagon in patients with arginine vasopressin deficiency (central diabetes insipidus) and healthy controls

Open Access
Arginine Vasopressin Deficiency
Original Article

Effective strategies for pregnancy and lactation-associated osteoporosis: teriparatide use in focus

Lactation
Review

Relation between blood pressure time in range and composite cardiovascular outcomes in patients with primary aldosteronism: a retrospective case study

Hypertension
Original Article

Continuous glucose monitoring profile in COVID-19 patients with and without diabetes receiving methylprednisolone

COVID-19
Original Article

Women’s health knowledge hub

Menopause
Clinical Collection

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Live
Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital

Prof. Ronald F. van Vollenhoven

Developed by: Springer Medicine

Keynote series | Spotlight on managing health in obesity

Springer Medicine

Immune checkpoint inhibitors-induced diabetes mellitus (review)

Abstract

Other articles of this Issue 2/2024

Correction: Novel protective circulating miRNA are associated with preserved vitamin D levels in patients with mild COVID-19 presentation at hospital admission not progressing into severe disease

BMI z-score as a prognostic factor for height velocity in children treated with recombinant human growth hormone due to idiopathic growth hormone deficiency

Plasma oxytocin levels in response to glucagon in patients with arginine vasopressin deficiency (central diabetes insipidus) and healthy controls

Effective strategies for pregnancy and lactation-associated osteoporosis: teriparatide use in focus

Relation between blood pressure time in range and composite cardiovascular outcomes in patients with primary aldosteronism: a retrospective case study

Continuous glucose monitoring profile in COVID-19 patients with and without diabetes receiving methylprednisolone

Women’s health knowledge hub

Keynote webinar | Spotlight on advances in lupus

Keynote series | Spotlight on managing health in obesity

Springer Medicine

Abstract

Please log in to get access to this content